Company intelligence / Profile preview

Provell Pharmaceuticals

Honey Brook, Pennsylvania, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Provell Pharmaceuticals was primarily focused on distributing branded drugs like Euthyrox (levothyroxine) for hypothyroidism in the US, using a direct-to-consumer model to reduce costs by excluding pharmacy benefit manager intermediaries. They emphasized rigorous quality controls, including blister packaging for stability in narrow therapeutic index drugs, but ceased operations after financial challenges with suppliers.

Therapeutic areas: OncologyEndocrinology
Modalities: Small molecule
Industry: Biotech

Partnerships

Merck KGaA (licensed source of Euthyrox)Mark Cuban Cost Plus Drug Company (distribution partnership)

Beyond the preview

Go deeper on Provell Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Provell Pharmaceuticals.

Explore the full profile